Kamada

Company Overview

Snapshot

Founded in December 1990 by David Tsur, Kamada operates with 201–500 employees. The company has raised a total of $150 million across 7 funding rounds from 2 investors.

Business overview

Kamada is a biopharmaceutical company specializing in plasma-derived protein therapeutics. The company leverages its proprietary platform technology to extract and purify proteins from human plasma, developing a commercial product portfolio and a late-stage clinical pipeline. Kamada's offerings include FDA-approved products like GLASSIA for Alpha-1 Antitrypsin (AAT) deficiency and KEDRAB, a rabies immune globulin. The company serves global markets within the Health Tech & Life Sciences sector, specifically targeting healthcare providers and pharmaceuticals with its range of products for critical care, respiratory conditions, and other therapeutic areas.

Strategic signal

In September 2024, Kamada announced the expansion of its plasma collection operations in Texas with the opening of a new site in Houston. This strategic move indicates the company's commitment to strengthening its supply chain and increasing its capacity for plasma-derived product manufacturing, signaling potential for enhanced market reach and production capabilities to investors.

Company Intelligence Q&A

What was a significant recent operational expansion for Kamada?

In September 2024, Kamada announced the expansion of its plasma collection operations in Texas, opening a new site in Houston. This move aims to enhance the company's plasma supply chain.

When did Kamada last provide an update on its Israeli operations?

In October 2023, Kamada provided a corporate update on its Israel operations.

What was a key achievement for Kamada concerning CYTOGAM® in 2023?

In October 2023, Kamada announced achievements with CYTOGAM®, including the availability of the product manufactured by the company for U.S. commercial sale and the presentation of new clinical data.

When did Kamada announce its strategic acquisition to become a global leader in hyperimmune plasma?

In November 2021, Kamada announced a strategic transformational transaction, positioning the company as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved commercial products.